Rising prevalence of chronic skin diseases such as eczema and psoriasis is expected to drive the growth of the Pruritus Therapeutics Market. The increasing geriatric population worldwide is also contributing to the growth of the market, as elderly individuals are more prone to developing pruritus. Additionally, advancements in research and development of novel therapeutics for the treatment of pruritus are creating opportunities for market growth.
Industry
Report Coverage | Details |
---|---|
Segments Covered | Disease Type, Product |
Regions Covered | • North America (United States, Canada, Mexico) • Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe) • Asia Pacific (China, Japan, South Korea, Singapore, India, Australia, Rest of APAC) • Latin America (Argentina, Brazil, Rest of South America) • Middle East & Africa (GCC, South Africa, Rest of MEA) |
Company Profiled | Abbvie,, Actavis Plc, Amgen,, Astellas Pharma, Bristol-Myers Squibb, Cara Therapeutics, GlaxoSmithKline, Plc., Myaln NV, Novartis AG, Pfizer, Sanofi, Teva Pharmaceuticals |
High cost of pruritus therapeutics is A primary hindrance for the market. The expensive nature of these treatments can limit the access to care for patients, especially in developing countries where healthcare resources are scarce. Furthermore, lack of awareness about pruritus and its treatment options among both patients and healthcare providers can act as a restraint for market growth.